Synthesis of a β-glycoside functionalized GΛC motif for self-assembly into rosette nanotubes with predefined length
摘要:
Progress toward the synthesis of guanine cytosine (G Lambda C) oligonucleotides for the spontaneous self-assembly of rosette nanotubes (RNTs) with predefined length is described. Highlighted is the synthesis of the beta-glycoside functionalized G Lambda C base along with a new nitrogen protecting group strategy that is compatible with Boc and Bn groups. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
[EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DU COMPLÉMENT
申请人:NOVARTIS AG
公开号:WO2014002053A1
公开(公告)日:2014-01-03
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. (C) 2016 Elsevier Masson SAS. All rights reserved.
Aliphatic Organo-functional Siloxanes<sup>1</sup>
作者:L. H. Sommer、R. P. Pioch、N. S. Marans、G. M. Goldberg、J. Rockett、J. Kerlin
DOI:10.1021/ja01108a042
日期:1953.6
NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS
申请人:[en]ICAGEN, LLC
公开号:WO2023091554A1
公开(公告)日:2023-05-25
The invention provides new heteroaromatic compounds having the general formula (I'), or a solvate or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, and n are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.